CCR2 inhibition was reported to reduce CD11b+/Ly6Chi/PD-L1+ MDSC enrichment in established gliomas and enhance PD-1 blockade efficacy in anti-PD-1 resistant gliomas [125]. The gene discussed is CCR2; the disease is central nervous system cancer.